Ashland Shorts Build Ahead of Today's Print

ASH heads into its fiscal fourth-quarter earnings today with a meaningful short position building against a stock that has quietly recovered, and an activist on the register with a point to prove.

Short sellers have been adding exposure with unusual persistence. Short interest has climbed nearly 19% over the past month to almost 11% of the free float, a genuinely elevated level for a mid-cap specialty chemicals name. The pace of accumulation tells the story: positions grew steadily through October before a 7.6% single-day reduction on November 2, bringing the count back to roughly 5 million shares. Despite that partial unwind, short interest remains near its recent high. Borrowing is not particularly aggressive, the cost to borrow sits at 0.56%, modest by any measure. Availability is ample at 246%, well above the 52-week floor of 146%, which means shorts face no meaningful squeeze pressure from the lending market. The ORTEX short score of 69.3 ranks ASH in the second percentile of its universe for short positioning, a signal that the bearish thesis here is institutionally held rather than retail-driven.

The debate between bulls and bears centers on whether Ashland's operational recovery is real or fragile. The bull case rests on a stock that has gained roughly 27% year to date, an analyst consensus tilting positive, and a mean price target of $80.45 implying around 10% further upside from current levels near $73. UBS, carrying a Buy rating, trimmed its target from $83 to $80 in early October but kept the conviction call intact. JPMorgan, Morgan Stanley, and several others lifted targets following the July print. Bears, reflected in that elevated short interest, appear focused on valuation: at an EV/EBITDA of about 10x with EPS surprise ranking in just the 22nd percentile historically, there is little margin for a disappointment. The factor score on EV/EBIT sits in the 10th percentile, suggesting the market is not cheap on earnings power alone.

The ownership picture adds a sharper edge to this print. Standard Investments LLC, an activist carrying a Schedule 13D, holds roughly 9.9% of shares and has been building steadily, raising its stake from 7.87% to 8.94% as last disclosed in May. Eminence Capital also filed a 13D/A in January 2025. Two activists on the register, alongside BlackRock lifting its holding to 12.3% of shares, reflects genuine conviction in a restructuring or strategic outcome. Omega Advisors, associated with Leon Cooperman, disclosed a fresh 6.4% stake in August. This density of active holders means today's print is as much about strategic direction and margin recovery as it is about any single quarter's revenue line. Retail attention has also picked up, with Wikipedia page views running more than two standard deviations above their 90-day average as of late October.

Today's report will test whether the operational momentum that drove a string of target-price upgrades through the summer is durable enough to satisfy activists who have put real capital behind the thesis, and to begin eroding the conviction of the short position that has quietly grown to one of the most elevated in the specialty chemicals sector.